GlassScriptPhysician profile
Azhar Shakeel
NPI 1114124674
$622.16
in general payments reported to CMS, 2019-2025
13 companies · $72.01 in 2025
The $72.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $163 · 2021: $140 · 2022: $48.13 · 2024: $69.83 · 2025: $72.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $131.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.70 | 2024-2025 | Airsupra |
| Glaxosmithkline, LLC. | $101.13 | 2021-2022 | |
| Genentech USA, INC. | $47.46 | 2020-2022 | |
| Allergan, INC. | $40.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $38.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.67 | 2020 | |
| Abbvie INC. | $19.35 | 2021 | |
| Merck Sharp & Dohme LLC | $17.65 | 2019 | |
| Amgen INC. | $16.39 | 2020 | |
| Mission Pharmacal Company | $15.76 | 2019 | |
| Medline Industries LP | $15.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azhar Shakeel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.